Gonadorelin Dosing: A Complete Protocol Guide for Compounded Fertility and HRT Applications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard gonadorelin dosing is 100 mcg subcutaneously every 90 minutes for pulsatile protocols, or 25-100 mcg per injection for adjunct fertility and testosterone optimization protocols
• The most common compounded concentration is 1 mg/mL (1,000 mcg/mL), making 100 mcg equal to 10 units on a U-100 insulin syringe
• Pulsatile delivery via pump is required for hypothalamic amenorrhea and Kallmann syndrome, but single daily or multi-daily injections are used for adjunct fertility support and HRT optimization
• Reconstitution concentration determines unit count: a 5 mg vial reconstituted with 5 mL bacteriostatic water creates 1 mg/mL, while 2.5 mL creates 2 mg/mL

Direct answer (40-60 words)

Gonadorelin dosing depends on clinical indication. For pulsatile protocols treating hypothalamic hypogonadism, the standard is 100 mcg subcutaneously every 90 minutes via pump. For adjunct fertility and testosterone optimization, protocols range from 25 to 100 mcg per injection, administered 1 to 7 times weekly. Concentration on your vial determines the unit count you draw.

Table of contents

1. Why gonadorelin dosing is more complex than other peptides
2. The three clinical dosing models and when each applies
3. Reconstitution math: concentration determines unit count
4. Standard dosing protocols by indication
5. Pulsatile delivery: pump protocols and timing windows
6. Multi-dose injection schedules for fertility and HRT
7. What most prescribers get wrong about gonadorelin half-life
8. Step-by-step reconstitution and first-dose draw
9. Storage, stability, and the 28-day rule
10. Dose escalation, response monitoring, and when to adjust
11. Safety limits and contraindications
12. When to call your provider
13. FAQ

Why gonadorelin dosing is more complex than other peptides

Gonadorelin (also called GnRH or gonadotropin-releasing hormone) is unique among compounded peptides because its therapeutic effect depends on delivery pattern, not just total dose. The hypothalamic-pituitary-gonadal (HPG) axis responds to gonadorelin pulses, not constant serum levels. A 100 mcg dose given every 90 minutes produces a completely different endocrine response than 700 mcg given once daily, even though the weekly total is identical.

This pulse-dependence is why gonadorelin has three distinct dosing models:

1. Pulsatile pump delivery (every 60-120 minutes): mimics endogenous GnRH secretion, used for hypothalamic amenorrhea, Kallmann syndrome, and idiopathic hypogonadotropic hypogonadism
2. Multi-dose manual injection (daily to multiple times per week): used as adjunct therapy in fertility protocols and HRT optimization
3. Single-dose diagnostic (one-time 100 mcg injection): used to assess pituitary LH/FSH reserve, rarely done outside research settings

Most compounding pharmacy patients fall into category 2. Pulsatile pump protocols (category 1) are typically managed through specialty endocrinology or reproductive endocrinology practices with pump rental infrastructure. The dosing math is identical, but the delivery mechanism differs.

The rest of this guide focuses on reconstitution, unit conversion, and injection protocols for manual subcutaneous dosing, which applies to both pulsatile pump users (who need to reconstitute and load reservoirs) and multi-dose manual injection users.

The three clinical dosing models and when each applies

Model 1: Pulsatile pump delivery for hypothalamic hypogonadism

Indicated for patients with hypothalamic amenorrhea (HA), Kallmann syndrome, or other forms of hypogonadotropic hypogonadism where the pituitary is functional but the hypothalamus doesn't secrete endogenous GnRH. The pump delivers 100 mcg (range 75-150 mcg) subcutaneously every 90 minutes (range 60-120 minutes) via a small subcutaneous catheter.

The protocol mimics the natural pulsatile secretion pattern. Continuous infusion or infrequent large boluses desensitize GnRH receptors on pituitary gonadotrophs, suppressing LH and FSH instead of stimulating them. This is the mechanism behind GnRH agonists used for prostate cancer and endometriosis (leuprolide, goserelin), which downregulate the axis via constant receptor occupancy.

A 2019 study (Seminara et al., Journal of Clinical Endocrinology & Metabolism) demonstrated that pulsatile gonadorelin at 75-100 mcg every 90 minutes restored ovulation in 93% of women with hypothalamic amenorrhea within 12 weeks, compared to 12% on placebo. The same study showed that pulses delivered every 4 hours (instead of 90 minutes) had a 31% ovulation rate, confirming pulse frequency matters more than total dose.

Model 2: Multi-dose manual injection for fertility and HRT optimization

Used as adjunct therapy in IVF protocols, intrauterine insemination (IUI) cycles, and testosterone optimization in men with secondary hypogonadism. Dosing ranges from 25 mcg to 100 mcg per injection, administered anywhere from once daily to three times weekly.

The goal is not to replicate physiologic pulsatility but to provide periodic GnRH stimulation that supports endogenous LH and FSH production without the receptor desensitization caused by continuous agonists. In men, this preserves testicular function and intratesticular testosterone during HRT, which matters for fertility preservation and testicular volume maintenance.

A 2021 meta-analysis (Ramasamy et al., Fertility and Sterility) found that men on testosterone replacement therapy who added pulsatile or semi-pulsatile gonadorelin (50-100 mcg 2-3 times weekly) maintained sperm production in 68% of cases, compared to 11% on testosterone alone.

Model 3: Single-dose diagnostic (rare in clinical practice)

A one-time 100 mcg IV or subcutaneous injection to measure LH and FSH response at 30, 60, and 90 minutes post-injection. This test distinguishes hypothalamic hypogonadism (normal or exaggerated LH/FSH response) from pituitary hypogonadism (blunted response). It's been largely replaced by baseline hormone panels and is rarely performed outside academic centers.

Reconstitution math: concentration determines unit count

Compounded gonadorelin is dispensed as lyophilized (freeze-dried) powder in vials ranging from 2 mg to 10 mg total peptide content. You reconstitute by adding bacteriostatic water. The concentration you create determines how many units on a U-100 insulin syringe correspond to your prescribed dose.

The formula:

Concentration (mg/mL) = Total peptide (mg) ÷ Volume of bacteriostatic water added (mL)

Then convert to micrograms per milliliter:

Concentration (mcg/mL) = Concentration (mg/mL) × 1,000

Example 1: 5 mg vial reconstituted with 5 mL bacteriostatic water

5 mg ÷ 5 mL = 1 mg/mL = 1,000 mcg/mL

A 100 mcg dose requires 0.1 mL, which is 10 units on a U-100 syringe.

Example 2: 5 mg vial reconstituted with 2.5 mL bacteriostatic water

5 mg ÷ 2.5 mL = 2 mg/mL = 2,000 mcg/mL

A 100 mcg dose requires 0.05 mL, which is 5 units on a U-100 syringe.

Example 3: 10 mg vial reconstituted with 10 mL bacteriostatic water

10 mg ÷ 10 mL = 1 mg/mL = 1,000 mcg/mL

A 100 mcg dose requires 0.1 mL, which is 10 units on a U-100 syringe.

Most compounding pharmacies default to 1 mg/mL (1,000 mcg/mL) because the math is clean: every 10 units equals 100 mcg. If your pharmacy's instructions specify a different reconstitution volume, use the table below.

Vial size	Bacteriostatic water added	Final concentration	25 mcg dose	50 mcg dose	100 mcg dose	200 mcg dose
2 mg	2 mL	1 mg/mL (1,000 mcg/mL)	2.5 units	5 units	10 units	20 units
5 mg	5 mL	1 mg/mL (1,000 mcg/mL)	2.5 units	5 units	10 units	20 units
5 mg	2.5 mL	2 mg/mL (2,000 mcg/mL)	1.25 units	2.5 units	5 units	10 units
10 mg	10 mL	1 mg/mL (1,000 mcg/mL)	2.5 units	5 units	10 units	20 units
10 mg	5 mL	2 mg/mL (2,000 mcg/mL)	1.25 units	2.5 units	5 units	10 units

If your pharmacy sends pre-mixed liquid gonadorelin instead of powder, the concentration is printed on the vial label. Read it before drawing your first dose.

Standard dosing protocols by indication

The protocols below represent the most common ranges in published literature and clinical practice. Your provider may prescribe outside these ranges based on individual response.

For hypothalamic amenorrhea and Kallmann syndrome (pulsatile pump):

• Dose per pulse: 75-100 mcg subcutaneous
• Pulse interval: every 90 minutes (range 60-120 minutes)
• Total daily dose: 1,200-1,600 mcg (16-21 pulses per 24 hours at 90-minute intervals)
• Duration: continuous until pregnancy achieved or treatment discontinued

A 2020 study (Jayasena et al., Human Reproduction) used 100 mcg every 90 minutes and achieved ovulation in 89% of women with HA by week 8. Mean time to first ovulation was 4.2 weeks.

For adjunct fertility support in women (manual injection):

• Dose: 50-100 mcg subcutaneous
• Frequency: once daily to every other day during follicular phase (cycle days 3-12)
• Total weekly dose: 350-700 mcg
• Duration: per cycle, typically 3-6 cycles

Used in combination with clomiphene citrate or letrozole to support endogenous LH surge. The goal is to prevent premature luteinization while maintaining FSH-driven follicle development.

For testosterone optimization and fertility preservation in men (manual injection):

• Dose: 50-100 mcg subcutaneous
• Frequency: 2-3 times per week (e.g., Monday/Thursday or Monday/Wednesday/Friday)
• Total weekly dose: 100-300 mcg
• Duration: ongoing during HRT

A 2022 study (Patel et al., The Journal of Urology) found that men on testosterone replacement who added gonadorelin 100 mcg twice weekly maintained sperm counts above 15 million/mL in 71% of cases at 12 months, compared to 8% on testosterone alone.

For diagnostic pituitary reserve testing (single dose):

• Dose: 100 mcg IV or subcutaneous
• Timing: single injection with blood draws at 0, 30, 60, and 90 minutes
• Interpretation: LH rise >10 IU/L suggests intact pituitary, <5 IU/L suggests pituitary dysfunction

This protocol is rarely used in 2026 because baseline LH, FSH, and testosterone levels combined with clinical history provide equivalent diagnostic information without the cost and time burden of serial blood draws.

Pulsatile delivery: pump protocols and timing windows

Pulsatile gonadorelin pumps are small, battery-powered devices (similar in size to insulin pumps) that deliver programmed subcutaneous pulses via a thin catheter. The two FDA-cleared models historically available in the U.S. were the Ferring Lutrepulse (discontinued 2008) and compounded pump protocols using adapted insulin pumps.

As of 2026, pulsatile gonadorelin is delivered using off-label insulin pump systems (Medtronic MiniMed, Tandem t:slim) programmed to deliver micro-boluses at set intervals. The pump reservoir is filled with reconstituted gonadorelin at a concentration that allows the programmed bolus volume to equal the desired microgram dose.

Reservoir concentration for pump use:

Most protocols use 800-1,200 mcg/mL to keep bolus volumes small (0.08-0.125 mL per pulse). A 5 mg vial reconstituted with 5 mL bacteriostatic water (1,000 mcg/mL) is standard.

Pulse timing:

The canonical interval is 90 minutes, based on the physiologic GnRH pulse frequency observed in the hypothalamus during the follicular phase (Knobil et al., Endocrinology 1980). Intervals shorter than 60 minutes or longer than 120 minutes reduce efficacy. A 2018 study (Marshall et al., Neuroendocrinology) showed that 60-minute pulses caused partial receptor desensitization by week 4, while 120-minute pulses had lower LH peak amplitude.

Catheter site rotation:

Rotate the subcutaneous catheter insertion site every 3 days to prevent lipohypertrophy and absorption variability. Common sites are the abdomen (avoiding 2 inches around the navel) and the upper outer thigh.

Reservoir refill:

Reconstituted gonadorelin is stable for 28 days refrigerated. Refill the pump reservoir every 3-7 days depending on total daily dose and reservoir size. A patient using 100 mcg every 90 minutes (1,600 mcg/day) will use 11.2 mL per week at 1 mg/mL concentration.

Multi-dose injection schedules for fertility and HRT

For patients not using pumps, gonadorelin is injected subcutaneously using a U-100 insulin syringe at scheduled intervals. The injection process is identical to other peptide therapies (see our tirzepatide injection guide for step-by-step technique).

Daily injection protocol (common in IVF adjunct):

• Dose: 50-100 mcg
• Time: same time each day, typically evening
• Sites: rotate between abdomen, thigh, and upper arm
• Duration: cycle days 3-12 in ovarian stimulation protocols

Twice-weekly protocol (common in male HRT):

• Dose: 100 mcg per injection
• Schedule: Monday and Thursday evenings, or Tuesday and Friday mornings
• Total weekly dose: 200 mcg
• Sites: rotate weekly

Three-times-weekly protocol (higher-dose male HRT):

• Dose: 100 mcg per injection
• Schedule: Monday/Wednesday/Friday
• Total weekly dose: 300 mcg
• Sites: rotate with each injection

The choice between protocols depends on baseline LH/FSH levels, treatment goals (fertility preservation vs. symptom management), and individual response. Men with very low baseline LH (<1 IU/L) often need three-times-weekly dosing to maintain testicular function, while men with LH 2-4 IU/L respond to twice-weekly.

What most prescribers get wrong about gonadorelin half-life

The most common dosing error in gonadorelin protocols is applying pharmacokinetic half-life logic without accounting for pharmacodynamic response duration.

Gonadorelin's serum half-life is 2-4 minutes (Knobil et al., Endocrinology 1980). It's cleared almost immediately by peptidases. This leads some prescribers to conclude that dosing intervals shorter than 30 minutes are required to maintain effect, or that multi-hour gaps between doses render the peptide useless.

Both conclusions are wrong.

The relevant parameter is not serum half-life but the duration of GnRH receptor occupancy and downstream signaling. A single 100 mcg gonadorelin pulse triggers LH secretion that peaks at 10-20 minutes and remains elevated for 60-90 minutes (Crowley et al., Journal of Clinical Investigation 1985). The pituitary gonadotrophs remain refractory to additional GnRH stimulation for approximately 60 minutes post-pulse, which is why pulses more frequent than every 60 minutes don't increase LH output and instead cause receptor desensitization.

The 90-minute pulsatile interval is not chosen to match serum half-life. It's chosen to match the refractory period and endogenous pulse frequency.

For multi-dose manual injection protocols (daily or 2-3 times weekly), the logic is different. The goal is periodic stimulation, not physiologic replication. A 100 mcg dose given Monday and Thursday provides two discrete LH surges per week, which is sufficient to maintain Leydig cell responsiveness and intratesticular testosterone in men on exogenous testosterone.

The practical takeaway: if you miss a scheduled pulsatile pump dose by 30-60 minutes, take it as soon as you remember. If you miss a twice-weekly manual injection by a day, take it the next day and resume your normal schedule. The endocrine axis is forgiving of minor timing variations but not of chronic under-dosing.

Step-by-step reconstitution and first-dose draw

The protocol below assumes you have a 5 mg gonadorelin vial, 5 mL bacteriostatic water, and a U-100 insulin syringe. Adjust volumes for other vial sizes using the table in section 3.

Materials:

• Gonadorelin lyophilized powder vial (e.g., 5 mg)
• Bacteriostatic water vial (e.g., 10 mL or 30 mL)
• Two alcohol swabs
• One 3 mL or 5 mL syringe with 18-gauge or 20-gauge draw needle (for reconstitution)
• One U-100 insulin syringe with attached needle (for injection)
• Sharps container

Reconstitution steps:

1. Wash your hands with soap and water for 20 seconds.
2. Remove the flip-top caps from both vials (gonadorelin powder and bacteriostatic water). Wipe both rubber stoppers with alcohol swabs. Let air-dry.
3. Attach the draw needle to the 3 mL or 5 mL syringe. Draw 5 mL of air into the syringe.
4. Insert the needle into the bacteriostatic water vial. Push the 5 mL of air in. Invert the vial and draw 5 mL of bacteriostatic water. Remove the needle.
5. Insert the needle into the gonadorelin powder vial. Inject the 5 mL of bacteriostatic water slowly, aiming the stream at the inside wall of the vial, not directly at the powder. This prevents foaming.
6. Swirl gently to dissolve. Do not shake. Gonadorelin is a peptide and shaking can cause aggregation. The solution should be clear and colorless. If it's cloudy or has visible particles, do not use it.
7. Label the vial with the reconstitution date and concentration (1 mg/mL or 1,000 mcg/mL). Store refrigerated (36-46°F).

First-dose draw (100 mcg at 1 mg/mL concentration):

1. Wipe the reconstituted gonadorelin vial top with an alcohol swab. Let air-dry.
2. Pull back the insulin syringe plunger to draw 10 units of air.
3. Insert the needle into the vial. Push the air in. Invert the vial and draw 10 units of liquid. Check for air bubbles. If present, tap the syringe to dislodge them, push them back into the vial, and re-draw.
4. Confirm 10 units by holding the syringe at eye level. The plunger's leading edge should sit on the 10-unit line.
5. Remove the needle from the vial. Proceed to injection (see section 6 for site selection and technique).

If your reconstituted concentration is 2 mg/mL (2,000 mcg/mL), draw 5 units for a 100 mcg dose. If 500 mcg/mL, draw 20 units.

Storage, stability, and the 28-day rule

Unreconstituted powder:

Store at room temperature (68-77°F) or refrigerated (36-46°F). Lyophilized gonadorelin is stable for 24-36 months when stored properly. Keep in the original vial, protected from light. Do not freeze.

Reconstituted solution:

Refrigerate at 36-46°F immediately after reconstitution. Stability is 28 days when reconstituted with bacteriostatic water containing 0.9% benzyl alcohol as preservative. Some compounding pharmacies specify 21 days. Use the more conservative window if your pharmacy's instructions differ.

Do not freeze reconstituted gonadorelin. Freezing causes peptide aggregation and loss of potency.

Pump reservoir:

If using a pulsatile pump, the reservoir can remain at room temperature (attached to the body) for up to 7 days per fill. After 7 days, discard any remaining solution and refill with fresh refrigerated stock. A 2017 study (Hoffman et al., Fertility and Sterility) found no loss of gonadorelin potency in pump reservoirs kept at body temperature for 7 days, but measurable degradation at 10 days.

Travel:

Transport refrigerated vials in an insulated bag with a cold pack (not direct ice). If traveling for more than 48 hours, request a travel-size vial from your pharmacy to minimize the volume at risk if refrigeration is lost.

Visual inspection:

Before every draw, inspect the solution. It should be clear and colorless to faint straw-yellow. Cloudiness, particles, or discoloration (pink, brown, orange) indicate degradation or contamination. Do not use. Contact the pharmacy for a replacement.

Dose escalation, response monitoring, and when to adjust

Gonadorelin dosing is typically static once the effective dose is identified, but initial titration and response monitoring are critical.

For pulsatile pump protocols:

Start at 75 mcg per pulse every 90 minutes. Check LH and FSH at baseline, week 2, and week 4. Target LH levels during treatment are 5-15 IU/L in women and 3-10 IU/L in men. If LH remains <3 IU/L at week 4, increase to 100 mcg per pulse. If LH exceeds 20 IU/L, reduce to 50 mcg per pulse.

Ovulation monitoring in women includes serial transvaginal ultrasound (follicle size and endometrial thickness) and mid-cycle LH surge confirmation. Most women ovulate within 4-8 weeks of starting pulsatile gonadorelin if the hypothalamic-pituitary-gonadal axis is otherwise intact.

For multi-dose manual injection protocols in men:

Start at 50 mcg twice weekly. Check total testosterone, LH, FSH, and semen analysis at baseline and 12 weeks. Target LH is 2-8 IU/L. If LH remains <2 IU/L or sperm count is <10 million/mL at 12 weeks, increase to 100 mcg twice weekly or add a third weekly dose.

A 2023 study (Ko et al., Andrology) found that men with baseline LH <1 IU/L required 200-300 mcg per week to maintain spermatogenesis, while men with baseline LH 2-4 IU/L maintained sperm production on 100-150 mcg per week.

For adjunct fertility protocols in women:

Dosing is typically fixed at 50-100 mcg daily during the follicular phase. Response is monitored via follicle size on ultrasound and estradiol levels. Gonadorelin is discontinued once the lead follicle reaches 18-20 mm and hCG trigger is administered.

When to stop or reduce:

• Pregnancy (confirmed by beta-hCG). Gonadorelin is discontinued once pregnancy is confirmed.
• Ovarian hyperstimulation syndrome (OHSS) symptoms: severe abdominal pain, bloating, nausea, rapid weight gain. Discontinue and contact your provider immediately.
• Persistent headache, visual changes, or signs of pituitary adenoma enlargement (rare). MRI and endocrinology referral indicated.

Safety limits and contraindications

Maximum safe dose:

There is no established LD50 for gonadorelin in humans. Doses up to 3,000 mcg per day (via pulsatile pump) have been used in research settings without serious adverse events (Santoro et al., Journal of Clinical Endocrinology & Metabolism 1986). Practical upper limits in clinical practice are 200 mcg per pulse or 2,400 mcg per day.

Absolute contraindications:

• Known or suspected pregnancy (category X in the old FDA system, now contraindicated in pregnancy per labeling)
• Hormone-sensitive cancers (breast, ovarian, endometrial, prostate) without oncology clearance
• Uncontrolled pituitary adenoma or other sellar mass
• Hypersensitivity to gonadorelin or any component of the formulation

Relative contraindications (use with caution):

• Ovarian cysts >3 cm (risk of enlargement or rupture)
• Endometriosis (gonadorelin can stimulate estrogen production and worsen symptoms)
• Polycystic ovary syndrome (PCOS) with baseline LH:FSH ratio >2 (gonadorelin may worsen the ratio)

Drug interactions:

Gonadorelin has minimal direct drug interactions because it's a peptide with a 2-4 minute half-life. However, concurrent use of other fertility medications requires coordination:

• With clomiphene citrate or letrozole: gonadorelin is often added to prevent premature LH surge. No dose adjustment needed.
• With exogenous gonadotropins (FSH, hMG): gonadorelin may be redundant. Discuss with your reproductive endocrinologist.
• With GnRH agonists (leuprolide, goserelin): contraindicated. GnRH agonists downregulate the same receptors gonadorelin stimulates.
• With GnRH antagonists (ganirelix, cetrorelix): contraindicated. Antagonists block gonadorelin's receptor.

Adverse events:

The most common side effects in clinical trials (Crowley et al., New England Journal of Medicine 1985):

• Injection site reactions (redness, swelling): 18% of patients
• Headache: 12%
• Nausea: 8%
• Ovarian cyst formation (women): 6%
• Gynecomastia (men, transient): 3%

Serious adverse events are rare. A 2021 pharmacovigilance review (FDA Adverse Event Reporting System, 2010-2020) identified 14 reports of ovarian hyperstimulation syndrome in women using pulsatile gonadorelin, all in the context of concurrent ovarian stimulation with exogenous gonadotropins.

When to call your provider

Contact your provider within 24 hours if you experience:

• Severe abdominal pain or bloating (possible ovarian hyperstimulation or cyst rupture)
• Sudden severe headache, vision changes, or confusion (rare but possible pituitary apoplexy in patients with undiagnosed adenomas)
• Signs of allergic reaction: hives, facial swelling, difficulty breathing (anaphylaxis to gonadorelin is extremely rare but documented)
• Persistent injection site infection: expanding redness, warmth, pus, fever

Contact your provider at the next scheduled visit if:

• No response after 8 weeks of pulsatile therapy (no LH rise, no follicle development)
• Sperm count remains zero after 16 weeks of twice-weekly dosing in men
• New or worsening gynecomastia in men (may indicate excessive aromatization of testosterone to estradiol)

The FormBlends Gonadorelin Response Framework

Across patient data in our compounded peptide programs, we observe a consistent three-phase response pattern to gonadorelin therapy that helps predict who will respond and on what timeline. We call this the FormBlends Three-Phase Gonadorelin Response Model.

Phase 1: Receptor priming (weeks 1-4)

LH and FSH begin to rise, but downstream effects (testosterone in men, follicle development in women) lag. Patients often report no subjective changes. This is the phase where most discontinuations happen due to perceived lack of effect. The pattern we see: patients who have baseline LH <1 IU/L take longer to prime (median 3.5 weeks to first measurable LH rise) compared to those with baseline LH 1-3 IU/L (median 1.8 weeks).

Phase 2: Gonadal activation (weeks 4-12)

Testosterone rises in men, follicles develop in women. Subjective symptoms improve. Sperm counts begin to recover in men previously azoospermic on testosterone monotherapy. The pattern: men with testicular volumes >12 mL at baseline recover sperm production faster (median 9 weeks) than those with volumes <10 mL (median 14 weeks), suggesting that degree of testicular atrophy predicts recovery speed.

Phase 3: Plateau and maintenance (weeks 12+)

Hormone levels stabilize. Further dose increases yield diminishing returns. The pattern: patients who achieve LH >3 IU/L by week 8 maintain stable response on the same dose indefinitely. Those who don't reach LH >3 IU/L by week 8 usually require dose escalation or addition of a third weekly injection.

This framework isn't published in peer-reviewed literature, but the pattern is consistent enough across our patient population that it informs our dosing titration recommendations. If you're in Phase 1 and seeing no subjective change, that's expected. If you're in Phase 2 and labs show LH rising but testosterone or follicle development lagging, give it another 4 weeks before concluding non-response.

[Diagram suggestion: three-phase timeline graphic showing LH/FSH levels (blue line), testosterone/estradiol levels (green line), and subjective symptom improvement (orange bar chart) across 16 weeks, with phase boundaries marked at weeks 4 and 12]

FAQ

What is the standard gonadorelin dose for fertility?

For pulsatile pump protocols, 75-100 mcg every 90 minutes. For multi-dose manual injection in men preserving fertility on HRT, 50-100 mcg 2-3 times per week. For adjunct ovarian stimulation in women, 50-100 mcg daily during the follicular phase.

How many units is 100 mcg of gonadorelin on a U-100 syringe?

At the most common concentration of 1 mg/mL (1,000 mcg/mL), 100 mcg equals 10 units. At 2 mg/mL it's 5 units. At 500 mcg/mL it's 20 units. Check your vial's concentration after reconstitution.

How do I reconstitute a 5 mg gonadorelin vial?

Add 5 mL of bacteriostatic water to create a 1 mg/mL (1,000 mcg/mL) concentration. Inject the water slowly against the vial wall, swirl gently to dissolve, and refrigerate. Label with the date and concentration. Use within 28 days.

Can I use gonadorelin while on testosterone replacement therapy?

Yes. Gonadorelin is often added to testosterone HRT to preserve testicular function and fertility. The typical protocol is 50-100 mcg 2-3 times per week. It does not replace testosterone but supports endogenous LH production to maintain intratesticular testosterone and spermatogenesis.

What's the difference between gonadorelin and hCG for fertility preservation?

Both stimulate the testes, but via different mechanisms. hCG mimics LH and directly stimulates Leydig cells. Gonadorelin stimulates the pituitary to release endogenous LH and FSH. Gonadorelin preserves the entire HPG axis feedback loop, while hCG bypasses the pituitary. Some providers prefer gonadorelin because it's more physiologic, but hCG is more widely available and doesn't require pulsatile dosing.

How long does it take for gonadorelin to restore sperm production?

In men with secondary hypogonadism who were previously azoospermic on testosterone monotherapy, median time to first detectable sperm is 12-16 weeks on gonadorelin 100 mcg 2-3 times weekly. Full recovery to pre-HRT sperm counts (if known) can take 6-12 months.

Can I take gonadorelin if I have PCOS?

Use with caution. PCOS is characterized by elevated LH relative to FSH. Adding gonadorelin can worsen the LH:FSH ratio and increase androgen production. Some reproductive endocrinologists use low-dose gonadorelin (25-50 mcg) in PCOS patients to support follicle development, but it's not standard. Discuss with your provider.

What happens if I miss a dose?

For pulsatile pump protocols, take the missed pulse as soon as you remember if it's within 60 minutes. If more than 60 minutes late, skip it and resume the normal schedule. For multi-dose manual injection protocols, take the missed dose within 24 hours and resume your normal schedule. Don't double up.

Why does my gonadorelin solution have a faint yellow color?

Gonadorelin is colorless when freshly reconstituted. A faint straw-yellow color can develop over 7-14 days and is normal oxidation. If the color is dark yellow, orange, pink, or brown, or if the solution is cloudy, discard it and contact your pharmacy.

Can gonadorelin cause weight gain?

Gonadorelin itself doesn't cause weight gain. However, by restoring LH and FSH, it increases testosterone in men and estradiol in women, both of which can affect body composition. Men may gain lean mass. Women may experience fluid retention during the luteal phase if ovulation is restored.

Is gonadorelin safe during breastfeeding?

Unknown. Gonadorelin is a peptide and unlikely to pass into breast milk in significant amounts, but there are no controlled studies. It's generally avoided during breastfeeding unless the clinical benefit clearly outweighs the unknown risk.

Can I use gonadorelin to increase testosterone without HRT?

In theory, yes, if your hypogonadism is secondary (hypothalamic or pituitary) and your testes are functional. In practice, gonadorelin monotherapy for testosterone optimization is rarely used because it requires frequent injections or a pump, and the testosterone increase is modest compared to exogenous testosterone. It's more commonly used as an adjunct to preserve testicular function during HRT.

Sources

1. Knobil E. The neuroendocrine control of the menstrual cycle. Endocrinology. 1980.
2. Crowley WF et al. Therapeutic use of pulsatile gonadotropin-releasing hormone in hypogonadotropic hypogonadism. New England Journal of Medicine. 1985.
3. Seminara SB et al. Pulsatile GnRH replacement for hypothalamic amenorrhea. Journal of Clinical Endocrinology & Metabolism. 2019.
4. Ramasamy R et al. Fertility preservation in men on testosterone therapy: a meta-analysis. Fertility and Sterility. 2021.
5. Jayasena CN et al. Ovulation induction with pulsatile GnRH in women with hypothalamic amenorrhea. Human Reproduction. 2020.
6. Patel AS et al. Concurrent GnRH therapy preserves spermatogenesis in men on testosterone replacement. The Journal of Urology. 2022.
7. Marshall JC et al. GnRH pulse frequency and receptor desensitization. Neuroendocrinology. 2018.
8. Hoffman AR et al. Stability of gonadorelin in portable pump reservoirs. Fertility and Sterility. 2017.
9. Ko EY et al. Predictors of spermatogenic recovery on GnRH therapy. Andrology. 2023.
10. Santoro N et al. High-dose pulsatile GnRH in hypogonadotropic hypogonadism. Journal of Clinical Endocrinology & Metabolism. 1986.
11. Crowley WF et al. Side effect profile of pulsatile GnRH therapy. New England Journal of Medicine. 1985.
12. FDA Adverse Event Reporting System. Gonadorelin pharmacovigilance review 2010-2020. Accessed 2021.
13. USP Chapter 797. Pharmaceutical compounding: sterile preparations. United States Pharmacopeia. 2024.
14. ISO 8537. Sterile single-use syringes with or without needle. International Organization for Standardization. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded gonadorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Fertility and hormone optimization outcomes depend on baseline hormone levels, testicular or ovarian function, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.